RecruitingNot ApplicableNCT06880640

Affect-based Impulsivity in Borderline Personality Disorder

Affect-based Impulsivity in Borderline Personality Disorder: Developing a Neurocomputational Phenotype


Sponsor

University of North Carolina, Chapel Hill

Enrollment

106 participants

Start Date

Sep 21, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this research study is to investigate how personality traits and neuroendocrine systems relate to decision-making patterns in individuals 18-45 years old. The main question it aims to answer is how neuroendocrine activity impacts decision-making. Participants will complete online behavioral tasks, a stress induction procedure, self-report surveys, and a cognitive assessment. During the session, psychophysiological measures will be collected, including electrocardiogram (ECG) and cardiac impedance (ICG) to monitor heart rate and blood flow, as well as electrodermal activity (EDA), blood drop samples, and saliva collection to assess nervous system activity.


Eligibility

Min Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a behavioral approach called Stress Induction for people with borderline personality disorder (bpd) and healthy controls group - age and sex-matched. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALStress Induction

Participants will complete the Trier Social Stress Test to induce stress, which includes a public speaking simulation and mental arithmetic.


Locations(1)

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06880640


Related Trials